Search results for #MSKACCESS
🚀 We are extremely proud to announce the launch of MSK-ACCESS® powered with SOPHiA DDM™! We want to warmly thank everyone who joined our launch event in Switzerland and contributed to make this insightful gathering a success! #oncology #MSKACCESS #MSK #cancerresearch #AI
Happy to share our latest work in MSI-H/MMR-deficient lung cancers. Huge collaborative effort made possible through #MSKIMPACT #MSKACCESS profiling. Please check out our paper on the cover page of @JTOonline tinyurl.com/3wr9ymvf
Deeply appreciative of everyone who helped develop #MSKimpact, #MSKaccess, #MPath, @OncoKB, @cbioportal, and of the physicians, scientists, nurses, administrators, clinic staff, couriers & accessioners who deliver precision diagnostics day after day. @MSKPathology @MskccCMO
Deeply appreciative of everyone who helped develop #MSKimpact, #MSKaccess, #MPath, @OncoKB, @cbioportal, and of the physicians, scientists, nurses, administrators, clinic staff, couriers & accessioners who deliver precision diagnostics day after day. @MSKPathology @MskccCMO
Had a great time discussing biomarker testing and AI for lung cancer diagnosis! Multidisciplinary teamwork is so important! Thank you for the invite! @MSKPathology #MSKIMPACT #MSKFusion #MSKACCESS
Please check out our latest review on rare lung cancer subtypes! @MSKPathology #mskimpact #mskfusion #mskaccess
Please check out our latest review on rare lung cancer subtypes! @MSKPathology #mskimpact #mskfusion #mskaccess
cfDNA and #MSKaccess by @MFBerger1 #pancreaticcancer #mskpancreascme @CpcrMsk @MSKCME
Amazing! Pls check out our pan-cancer study on RET fusion detection using FISH, DNA/RNA-NGS, IHC and ctDNA bit.ly/3eY3AL8 @CCR_AACR @JackieHechtman @alexdrilon @MLadanyi @DrEzraRosen @MSKPathology @MSK_DeptOfMed #MSKIMPACT #MSKFusion #MSKACCESS
Amazing! Pls check out our pan-cancer study on RET fusion detection using FISH, DNA/RNA-NGS, IHC and ctDNA bit.ly/3eY3AL8 @CCR_AACR @JackieHechtman @alexdrilon @MLadanyi @DrEzraRosen @MSKPathology @MSK_DeptOfMed #MSKIMPACT #MSKFusion #MSKACCESS
Congrats Sara! @saradinaps for presenting the NYS validation data for #mskaccess Heme, a liquid biopsy NGS-based assay that would benefit #lymphoma patients at #AACR2022. @MSKPathology @ARoseBrannon @RPtash 👏 ⭐️
Congrats Sara! @saradinaps for presenting the NYS validation data for #mskaccess Heme, a liquid biopsy NGS-based assay that would benefit #lymphoma patients at #AACR2022. @MSKPathology @ARoseBrannon @RPtash 👏 ⭐️
#DNAsequencing #ngs #genomics @MSKCancerCenter: '.@saradinaps on “#MSKACCESS Heme: A cell-free DNA next-generation sequencing assay to identify somatic alterations in patients with #lymphoma,” which will allow for more … , see more tweetedtimes.com/v/9819?s=tnp
.@saradinaps on “#MSKACCESS Heme: A cell-free DNA next-generation sequencing assay to identify somatic alterations in patients with #lymphoma,” which will allow for more info to be gathered about a tumor in a noninvasive way. #AACR22
A simple blood draw can yield a wealth of lifesaving information. See how #MSKAccess, our in-house #LiquidBiopsy test, has allowed us to sequence thousands of tumors to help guide treatment decisions and detect recurrences earlier. #AACR22 bit.ly/3LTAqZ2
One of the most exciting developments in cancer care has been the increased use of #LiquidBiopsies to analyze tumors. Read more about #MSKAccess and how simple blood draw can yield a wealth of lifesaving information. @MLadanyi @MFBerger1 @ahmetz mskcc.org/news/how-cutti…
Continued leadership Memorial Sloan Kettering and their #MSKAccess cfDNA test from treatment selection. This manuscript offers a perspective and adds data to the debate on how to address somatic v germline and clonal hematopoiesis in cfDNA nature.com/articles/s4146…
Continued leadership Memorial Sloan Kettering and their #MSKAccess cfDNA test from treatment selection. This manuscript offers a perspective and adds data to the debate on how to address somatic v germline and clonal hematopoiesis in cfDNA nature.com/articles/s4146…
It was very satisfying to be part of this institutional effort to make a safer, less painful, and sometimes more informative method to profile patients' cancers. Thank you to everyone who put in tremendous work to bring #MSKaccess to life.
It was very satisfying to be part of this institutional effort to make a safer, less painful, and sometimes more informative method to profile patients' cancers. Thank you to everyone who put in tremendous work to bring #MSKaccess to life.
Finally out in @NatureComms, the validation and clinical experience of our plasma-based assay #MSKaccess rdcu.be/cmMyf. Thank you, my wonderful colleagues for the journey and reviewer #2 for making us more resilient, one question at a time...